Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
Stock Information for Matinas Biopharma Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.